The preliminary results also show differences in the β3-AR expression between CTCs derived from metastatic and non-metastatic patients, and suggest a possible role of β3-AR as a new marker to be combined with CD99 for the prediction of recurrence or disease severity in Ewing sarcoma patients. This evidence concerns the gene CD99 and Ewing sarcoma.